A phase II study found that treatment with atezolizumab and bevacizumab was well-tolerated and resulted in a 40% objective response rate in patients with advanced malignant peritoneal mesothelioma, a ...

Sugarbaker et al 1 are to be congratulated for their comprehensive review of the management of malignant peritoneal mesothelioma using cytoreductive surgery (CRS) and perioperative chemotherapy. Their ...

Survival update on a subset of peritoneal mesothelioma (PM) patients in an expanded access program (EAP) of pemetrexed (P) alone or combined with cisplatin in the treatment of malignant mesothelioma ...

Please provide your email address to receive an email when new articles are posted on . Atezolizumab plus bevacizumab appeared well-tolerated and resulted in a 40% objective response rate among ...

Mesothelioma is commonly linked to older men, but younger individuals can also be affected, leading to initial confusion and fear. Access to specialized treatment, such as hyperthermic intraperitoneal ...

Mesothelioma is a rare and aggressive tumor that, in many cases, results from exposure to asbestos. But over the last several decades, other causes of the disease have emerged, including treatment ...

Please provide your email address to receive an email when new articles are posted on . “In clinic, we have seen some people experience durable clinical benefit from pembrolizumab, so I was not ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A combination of ...